Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar;6(1):11-19.
doi: 10.1007/s40142-018-0133-1. Epub 2018 Feb 5.

Genetic Modifiers in Neurodegeneration

Nimansha Jain  1 , Alice S Chen-Plotkin  1
Affiliations

Genetic Modifiers in Neurodegeneration

Nimansha Jain et al. Curr Genet Med Rep. 2018 Mar.

Abstract

Purpose of review: To review the evidence for genetic modifier effects in the neurodegenerative diseases Huntington's Disease (HD), Frontotemporal Lobar Degeneration (FTLD), Alzheimer's Disease (AD), and Parkinson's Disease (PD).

Recent findings: Increasingly, we understand human disease genetics less through the lens of single-locus/single-trait effects, and more through that of polygenic contributions to disease risk. In addition, specific examples of genetic modifier effects of the chromosome 7 gene TMEM106B on various target genes including those causal for Mendelian classes of FTLD - GRN and c9orf72 - have emerged from both genetic cohort studies and mechanistic examinations of biological pathways.

Summary: Here, we summarize the literature reporting genetic modifier effects in HD, FTLD, AD, and PD. We further contextualize reported genetic modifier effects in these diseases in terms of insight they may lend to the concept of a polygenic landscape for the major neurodegenerative diseases.

Keywords: APOE; Alzheimer’s Disease; FTLD; Genetic modifier; Parkinson’s Disease; TMEM106B; neurodegeneration.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Both authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
A. Representation of types of genetic variants and effects on trait, with variant frequency on the X-axis and effect size on the Y-axis. Genetic modifier effects are represented by arrows emanating from target gene (blue dot) loci. B. Known genetic modifier effects in AD, PD, and FTLD. Target gene names are shown in red, and modifier loci names are shown in black, with direction of effect indicated by arrow. AD loci are highlighted by the pink oval, FTLD loci by the green oval, and PD loci by the tan oval. Arrows are not drawn to scale, and some genetic modifier loci are unknown (question marks).
See this image and copyright information in PMC

References

    1. Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743–800. doi: 10.1016/S0140-6736(15)60692-4.. - DOI - PMC - PubMed
    1. Bertram L. The genetic epidemiology of neurodegenerative disease. J Clin Invest. 2005;115:1449–57. doi: 10.1172/JCI24761.. - DOI - PMC - PubMed
    1. Gallagher MD, Posavi M, Huang P, Unger TL, Berlyand Y, Gruenewald AL, et al. A Dementia-Associated Risk Variant near TMEM106B Alters Chromatin Architecture and Gene Expression. Am J Hum Genet. 2017 doi: 10.1016/j.ajhg.2017.09.004. TMEM106B genetic modifier effect in FTLD due to c9orf72 expansion, demonstrated in 31-site international FTLD cohort. - DOI - PMC - PubMed
    1. Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014;42:D1001–6. doi: 10.1093/nar/gkt1229.. - DOI - PMC - PubMed
    1. Plomin R, Haworth CMA, Davis OSP. Common disorders are quantitative traits. Nat Rev Genet. 2010;10:872. doi: 10.1038/nrg2670.. - DOI - PubMed

LinkOut - more resources